Abstract
To improve treatment results in patients with surgically resectable T1-3NOMO small cell lung cancer, 16 patients were randomized to receive either neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy (cyclophosphamide, epirubicin, and etoposide). The overall survival is 45% at a median follow-up of 28.5 months. Patients treated with surgery plus adjuvant chemotherapy (n = 8) showed a significantly higher median and overall survival, proportion of 2-year survivors, and lower systemic relapse rate. These results indicate that the optimal treatment for T1-3NOMO small cell lung cancer is represented by the combination of surgery plus adjuvant chemotherapy.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / pathology
-
Carcinoma, Small Cell / surgery
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Epirubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Lung Neoplasms / surgery
-
Male
-
Middle Aged
-
Neoplasm Staging
Substances
-
Epirubicin
-
Etoposide
-
Cyclophosphamide